EGM of ICON plc Approves Stock Split
29 Septembre 2006 - 7:29PM
Business Wire
ICON (NASDAQ:ICLR), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, announced that at its Extraordinary General Meeting
held in Dublin today, all resolutions put to the meeting were
passed. These included a proposal to issue one new ordinary share
to the holder of each existing ordinary share, the effect of which
will be the equivalent of a two-for-one stock split. Following the
passing of this resolution, the issue of the new shares will be
made to the holders of record on October 13, 2006. ICON is a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries. We specialize in the
strategic development, management and analysis of programs that
support clinical development - from compound selection to Phase
I-IV clinical studies. ICON teams have successfully conducted over
1,900 development projects and over 2,300 consultancy engagements
across all major therapeutic areas. ICON currently has over 3,700
employees, operating from 45 locations in 30 countries. Further
information is available at http://www.iconclinical.com. The
statements made in this Press Release may contain forward-looking
statements that involve a number of risks and uncertainties. In
addition to the matters described in this Press Release, the
ability to maintain large client contracts or enter into new
contracts, maintain client relationships and the ability to manage
the opening of new offices, the integration of new business mergers
and acquisitions, as well as other risks and uncertainties detailed
from time to time in SEC reports filed by ICON, including its Form
20-F, F-1, S-8 and F-3, may affect the actual results achieved by
ICON. ICON disclaims any intent or obligation to update these
forward-looking statements. Source: ICON plc ICON (NASDAQ:ICLR), a
global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries,
announced that at its Extraordinary General Meeting held in Dublin
today, all resolutions put to the meeting were passed. These
included a proposal to issue one new ordinary share to the holder
of each existing ordinary share, the effect of which will be the
equivalent of a two-for-one stock split. Following the passing of
this resolution, the issue of the new shares will be made to the
holders of record on October 13, 2006. ICON is a global provider of
outsourced development services to the pharmaceutical,
biotechnology and medical device industries. We specialize in the
strategic development, management and analysis of programs that
support clinical development - from compound selection to Phase
I-IV clinical studies. ICON teams have successfully conducted over
1,900 development projects and over 2,300 consultancy engagements
across all major therapeutic areas. ICON currently has over 3,700
employees, operating from 45 locations in 30 countries. Further
information is available at http://www.iconclinical.com. The
statements made in this Press Release may contain forward-looking
statements that involve a number of risks and uncertainties. In
addition to the matters described in this Press Release, the
ability to maintain large client contracts or enter into new
contracts, maintain client relationships and the ability to manage
the opening of new offices, the integration of new business mergers
and acquisitions, as well as other risks and uncertainties detailed
from time to time in SEC reports filed by ICON, including its Form
20-F, F-1, S-8 and F-3, may affect the actual results achieved by
ICON. ICON disclaims any intent or obligation to update these
forward-looking statements. Source: ICON plc
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024